In June, Esperion Therapeutics Inc. (NASDAQ:ESPR), an Ann Arbor-based early-stage pharmaceutical company, raised $73 million in its IPO. It plans a secondary offering this year, based on trial results of its cholesterol-lowering drug. Esperion Therapeutics Inc (NASDAQ:ESPR) stock performance was -5.04% in last session and finished the day at $14.69. Traded volume was 31,400 shares in the last session and the average volume of the … Continue reading Losers to Watch: Esperion Therapeutics Inc (NASDAQ:ESPR), Egalet Corp (NASDAQ:EGLT), Ocera Therapeutics (NASDAQ:OCRX), La Jolla Pharmaceutical (NASDAQ:LJPC), Omeros (NASDAQ:OMER)